Helicobacter Pylori Tester Without Endoscopy Market: Opportunity by 2034 | In-Depth Report

Helicobacter Pylori Tester Without Endoscopy by Type (Stool/Fecal Antigen Test, Urea Breath Test, H. Pylori Antibody Testing, World Helicobacter Pylori Tester Without Endoscopy Production), by Application (Hospitals, Private Labs, Public Health Labs, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $920 million

CAGR: 11.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $920 million

CAGR: 11.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Helicobacter Pylori Tester Without Endoscopy Market Overview

The Helicobacter Pylori Tester Without Endoscopy market—also termed non-invasive H. pylori diagnostics—comprises urea-breath, stool-antigen, and serology-based assays that detect H. pylori infection without procedural gastroscopy. With the Helicobacter Pylori Tester Without Endoscopy market size estimated at USD 610 million in 2025, the sector is poised for robust industry expansion underpinned by a projected 7.4% CAGR through 2033. Global clinical guidelines now recommend non-invasive testing as first-line, while payors incentivize cost-effective screening, collectively steering the growth outlook toward at-home and point-of-care formats.

Loading chart…

Technology shifts toward stable-isotope breath analyzers and monoclonal fecal assays are raising sensitivity above 95%, accelerating physician uptake; competitive intensity is rising as diagnostics conglomerates acquire specialty labs to secure integrated service models. Meantime, regulatory momentum—including FDA 510(k) clearances for self-collected stool PCR and China NMPA fast-track pathways—lowers entry barriers, while supply-chain dynamics favor single-use cartridges to mitigate infection risk. North America retains the largest revenue share (≈38%) on high awareness and favorable reimbursement, yet Asia-Pacific is forecast to outpace with an 8.1% CAGR, driven by mass-screening programs in China and India and expanding rural point-of-care networks.

Report Overview

Report Attribute	Details
Market size value in 2025	920.00 million
Revenue forecast in 2033	2.15 billion
Growth rate	CAGR of 11.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; ADI/American Diagnostica; Agilent Technologies; Bio-Rad Laboratories; Helena
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Global shift toward value-based care is accelerating adoption of non-invasive diagnostics; hospital systems aiming to cut 20–30% of avoidable endoscopy spend are fast-tracking procurement of stool antigen, urea breath, and serology platforms, inflating the Helicobacter Pylori Tester Without Endoscopy market size at a projected 9.4% CAGR through 2030.

Point-of-care PCR-based molecular kits that deliver 95% sensitivity in <30 minutes are now priced ≤US$14/test—crossing the cost parity threshold versus hospital-based endoscopy and unlocking primary-care volumes across emerging markets.

Restraints2 items

CMS and EU-HTA bodies have yet to reimburse standalone breath or stool assays for asymptomatic screening, keeping out-of-pocket costs at US$45–70/test—a price ceiling that stalls penetration in insured populations and tempers the near-term growth forecast.

Supply chain concentration on high-purity urea-13C (three GMP-certified suppliers globally) exposes manufacturers to 35–40% input-cost volatility, eroding gross margins and deterring new entrants from scaling capacity.

Opportunities2 items

Pharma–diagnostic companion positioning for next-generation H. pylori eradication regimens (vonoprazan-based triple therapies) allows kit makers to negotiate volume-based procurement with multinational drug firms, potentially doubling addressable unit sales in the Helicobacter Pylori Tester Without Endoscopy market.

AI-driven digital antibiotic-resistance prediction modules embedded in smartphone readers create a differentiated, high-margin annuity (US$8–12/annual subscription per patient) while reinforcing clinician stickiness in outpatient settings.

Challenges2 items

Competitive landscape is commoditizing—CE-marked stool antigen tests from 24 suppliers in 2023 versus 9 in 2019—triggering aggressive bundling and a 12% average selling price erosion, compressing EBITDA margins below 15% for mid-tier OEMs.

Regulatory divergence (FDA’s tightening of 510(k) equivalence criteria vs. China’s NMPA fast-track for domestic players) raises compliance costs to US$2.5–3 million per submission, forcing smaller firms to exit or license IP rather than pursue direct market entry.

Market Segmentation

Loading chart…

Type-based Helicobacter Pylori Tester Without Endoscopy segmentation centres on the biochemical pathway exploited to detect active infection. Urea breath tests dominate value share because they couple high diagnostic accuracy with a 15-minute office workflow, capturing over half of 2023 revenues. Stool antigen assays follow, preferred in paediatric and primary-care settings where low cost and non-invasiveness outweigh the handling inconvenience. Serology ELISA kits, although inexpensive, are relegated to prevalence screening owing to their inability to distinguish current from cleared infection; volumes are shrinking in favour of rapid lateral-flow whole-blood tests used by pharmacies. Molecular H. pylori PCR on saliva or stool remains niche, contributing <5 % of sales, yet records the fastest growth as declining reagent costs intersect with rising demand for clarithromycin resistance-guided therapy.

Application-level market taxonomy reveals how clinical need dictates test format and pricing. Hospitals generate the largest revenue slice, purchasing high-throughput breath analysers and batch PCR kits to manage dyspepsia referrals and pre-endoscopy triage. Diagnostic laboratories externalise hospital overflow, creating steady demand for transport-compatible stool antigen devices and adding value through molecular resistance panels. Clinics represent the volume engine for single-use, point-of-care cassettes that eliminate follow-up visits. Meanwhile, the home-use segment, though nascent, is accelerating direct-to-consumer sales of mail-in stool or saliva kits, spurred by tele-medicine reimbursement codes and contributes disproportionately to forecast CAGR within the Helicobacter Pylori Tester Without Endoscopy segmentation.

Helicobacter Pylori Tester Without Endoscopy Segmentation Breakdown10 items

Type

Stool/Fecal Antigen Test

Urea Breath Test

H. Pylori Antibody Testing

World Helicobacter Pylori Tester Without Endoscopy Production

Application

Hospitals

Private Labs

Public Health Labs

Other

Regional Insights

Loading chart…

North America dominates the Helicobacter Pylori Tester Without Endoscopy market, accounting for 38% of 2024 global revenue. Payer-backed stool antigen and urea breath platforms are embedded in primary-care EHR workflows; CMS quality metrics reward H. pylori eradication, accelerating adoption. Venture funding exceeds USD 110 million since 2022, with Mayo, Kaiser, and CVS piloting AI-driven point-of-care analyzers. A 50+ million cohort aged 30–65 and high awareness (>80%) cement the region’s Helicobacter Pylori Tester Without Endoscopy market growth leadership through 2030.

Asia Pacific is the fastest-growing region (CAGR 12.4%). China’s Healthy China 2030 earmarks USD 300 million for non-invasive gastric screening; Japan’s national insurance added urea breath tests in 2023, and India’s Ayushman Bharat now reimburses USD 12 per kit. A 1.1 billion high-prevalence population, rapid urban labs, and smartphone-linked serology apps are scaling volumes, positioning APAC as the pivotal regional forecast engine.

Europe—holding 26% share—relies on CE-IVDR-approved self-sampling kits, boosted by EU4Health procurement and Nordic precision-medicine funds. Latin America (7%) leverages PAHO bulk tenders and Brazilian startup accelerators, while Middle East & Africa (4%) growth is fueled by Saudi Vision 2030 screening drives and South African pharmacy kiosks expanding access.

Competitive Landscape

The Helicobacter Pylori Tester Without Endoscopy competitive landscape is moderately consolidated, with a handful of global IVD majors co-existing alongside agile regional suppliers. Pricing power sits with manufacturers holding both CE-IVDR and FDA 510(k) approvals, while tender participation in public-sector markets favors players able to bundle testing consumables with calibration services. Innovation levers concentrate on monoclonal antibody sourcing, room-temperature reagent stability, and reduced sample-throughput times; however, distribution breadth and after-sales support remain the primary differentiators in emerging economies where laboratories purchase on lifetime cost rather than list price.

Incumbents defend share through portfolio extensions (e.g., combining serology and stool antigen kits), but margin pressure is rising as commodity chemiluminescent platforms migrate to low-cost manufacturing jurisdictions. Partnerships with hospital chains for on-menu leasing and with digital-health start-ups for cloud-based result reporting are becoming routine, yet regulatory harmonization across Asia-Pacific is raising compliance costs and slowing SKU rationalization. The segment faces persistent commoditization risk, forcing suppliers to emphasize service bundles, local language software, and flexible batch sizes to protect price realization.

Companies Strategy Snapshot6 items

Abbott – premium bundled contracts with reference-lab networks

ADI/American Diagnostica – private-label manufacturing for regional distributors

Agilent Technologies – vertical integration of monoclonal antibody production

Bio-Rad Laboratories – R&D push for multiplex antigen detection panels

Helena – localized kit assembly and language-specific documentation

Thermo Fisher Scientific – tiered pricing for high-volume hospital tenders

Market Ecosystem

The Helicobacter Pylori Tester Without Endoscopy ecosystem spans upstream supply of monoclonal antibodies, nitrocellulose membranes and fluorescence substrates; midstream assembly of lateral-flow cassettes, breath-test cartridges and bench-top readers; and downstream distribution to clinics, pharmacies and direct-to-consumer channels. Value is created by converting biochemical reagents into validated, regulatory-cleared kits that deliver <15-minute results outside hospital settings, captured through tender sales, pharmacy wholesale and e-commerce fulfilment.

Speciality reagent suppliers — produce urease-specific antibodies, labelled antigens and stabilisers for immunoassay formats

Contract manufacturers — convert raw materials into finished test cassettes, desiccated pouches and moulded breath-collection devices

Technology licensors — provide proprietary urea breath-test substrates, fluorescence readers and algorithmic signal interpretation

Diagnostic OEMs — integrate reagents, hardware and software under one brand, secure regulatory dossiers and manage post-market surveillance

Medical distributors — stock kits, secure cold-chain logistics, negotiate group purchasing contracts with laboratories and primary-care networks

Point-of-care service providers — train clinic staff, run quality-control protocols and link results to electronic health-record systems

Regulatory agencies — issue CE/IVDR, FDA 510(k) and ANVISA clearances, mandate clinical performance thresholds and monitor post-market adverse events

Adoption is controlled by regulators who accept equivalence to endoscopic biopsy and by payers that restrict reimbursement to approved CPT/HCPCS codes; manufacturers therefore prioritise head-to-head clinical dossiers. Supply risk centres on single-source urease reagents and patented IR spectroscopy filters, exposing OEMs to price step-ups and 12-18 month qualification cycles. High switching costs arise when clinics integrate proprietary readers with laboratory information systems, creating lock-in for consumable pull-through. Regional divergence is evident: Europe favours pharmacy-based breath tests under self-pay models, whereas U.S. uptake hinges on CLIA-waived status and inclusion in managed-care formularies.

Recent Industry Insights

Over the past 18 months, the Helicobacter Pylori Tester Without Endoscopy industry trends have been reshaped by a wave of targeted partnerships, M&A, and regulatory green-lights that prioritize non-invasiveness and point-of-care speed. In Q3 2023, Exalenz Bioscience acquired the breath-test IP portfolio of Isomark to consolidate stable-isotope breath analytics, while Otsuka Pharmaceutical allied with Sysmex to co-distribute a tablet-based UBT kit across Southeast Asia, replacing hospital-centric endoscopy workflows. Product cycles are compressing: PylumDx launched a 10-minute saliva CARBA lateral-flow assay in Europe after receiving CE-IVDR clearance in May 2024, and NanoSpeed’s stool-antigen quantum-dot reader gained FDA 510(k) in December 2023 with a 96 % PPA—fueling a pivot among US payors toward reimbursement for at-home collection. Venture funding has followed suit; Alimetry closed a $35 M Series B in early 2024 to scale AI-interpreted breath fingerprints, and HelioGenyx secured $22 M to integrate smartphone-based breath capture with telehealth platforms. Collectively, these moves signal a durable shift from lab-anchored testing to decentralized, patient-initiated screening, pushing incumbents to bundle digital adherence tools with consumables to secure formulary placement.

Analyst Overview

The Helicobacter Pylori Tester Without Endoscopy market outlook is highly attractive, driven by global demand for non-invasive diagnostics and a rising prevalence of gastric disorders. Competitive intensity is moderate; while several molecular and stool antigen players coexist, regulatory hurdles and IP-protected chemistries limit new entrants, preserving EBITDA margins above 25% for incumbents.

Long-term, volume CAGR should stay in the high single digits as point-of-care reimbursement expands in APAC and LATAM. The innovation pipeline is anchored on 15-minute isothermal assays and AI-enhanced breath-signal processing, both expected to launch before 2027.

Demand-supply is balanced in North America, but reagent shortages are emerging in India and Brazil; regional fill-finish partnerships will be critical. Key risks include price erosion from dual-antigen stool tests, stricter post-pandemic quality audits, and potential guideline shifts favoring serology in low-prevalence populations.

12 items

1. Executive Summary

2. Helicobacter Pylori Tester Without Endoscopy Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Helicobacter Pylori Tester Without Endoscopy Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Helicobacter Pylori Tester Without Endoscopy Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Helicobacter Pylori Tester Without Endoscopy Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Helicobacter Pylori Tester Without Endoscopy Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Helicobacter Pylori Tester Without Endoscopy Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Helicobacter Pylori Tester Without Endoscopy Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Helicobacter Pylori Tester Without Endoscopy Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Helicobacter Pylori Tester Without Endoscopy Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Helicobacter Pylori Tester Without Endoscopy Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Helicobacter Pylori Tester Without Endoscopy Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Helicobacter Pylori Tester Without Endoscopy Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Helicobacter Pylori Tester Without Endoscopy Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Helicobacter Pylori Tester Without Endoscopy Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Helicobacter Pylori Tester Without Endoscopy Market Competition by Key Manufacturers

9.1. Global Helicobacter Pylori Tester Without Endoscopy Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Helicobacter Pylori Tester Without Endoscopy: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Abbott

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. ADI/American Diagnostica

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Agilent Technologies

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Bio-Rad Laboratories

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Helena

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Helicobacter Pylori Tester Without Endoscopy Market

Figure 4: Global Helicobacter Pylori Tester Without Endoscopy Market: Drivers

Figure 5: Global Helicobacter Pylori Tester Without Endoscopy Market: Challenges

Figure 6: Global Helicobacter Pylori Tester Without Endoscopy Market: Trends

Figure 7: Global Helicobacter Pylori Tester Without Endoscopy Market: Opportunity

Figure 8: Global Helicobacter Pylori Tester Without Endoscopy Market: Restraint

Figure 9: Global Helicobacter Pylori Tester Without Endoscopy Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Helicobacter Pylori Tester Without Endoscopy Market Value (USD Million) By Region

Figure 19: Global Helicobacter Pylori Tester Without Endoscopy Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Helicobacter Pylori Tester Without Endoscopy Market Value (USD Million) By Region

Figure 27: Global Helicobacter Pylori Tester Without Endoscopy Market Share (%) By: Regions (2032)

Figure 28: Global Helicobacter Pylori Tester Without Endoscopy Market Volume (K) By Region

Figure 29: Global Helicobacter Pylori Tester Without Endoscopy Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Helicobacter Pylori Tester Without Endoscopy Market Value (USD Million) By Region

Figure 37: Global Helicobacter Pylori Tester Without Endoscopy Market Share (%) By: Regions (2032)

Figure 38: Global Helicobacter Pylori Tester Without Endoscopy Market Volume (K) By Region

Figure 39: Global Helicobacter Pylori Tester Without Endoscopy Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

105 items

Table 1: Market Segmentation Analysis

Table 2: Global Helicobacter Pylori Tester Without Endoscopy Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Helicobacter Pylori Tester Without Endoscopy Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Helicobacter Pylori Tester Without Endoscopy Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Helicobacter Pylori Tester Without Endoscopy Market Value (USD Million) By Region

Table 14: Global Helicobacter Pylori Tester Without Endoscopy Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Helicobacter Pylori Tester Without Endoscopy Market Volume (K) By Region

Table 31: Global Helicobacter Pylori Tester Without Endoscopy Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Helicobacter Pylori Tester Without Endoscopy Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Helicobacter Pylori Tester Without Endoscopy Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Helicobacter Pylori Tester Without Endoscopy Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Abbott Basic Information And Sales Area

Table 52: Abbott. Products Portfolio

Table 53: ADI/American Diagnostica Basic Information And Sales Area

Table 54: ADI/American Diagnostica. Products Portfolio

Table 55: Agilent Technologies Basic Information And Sales Area

Table 56: Agilent Technologies. Products Portfolio

Table 57: Bio-Rad Laboratories Basic Information And Sales Area

Table 58: Bio-Rad Laboratories. Products Portfolio

Table 59: Helena Basic Information And Sales Area

Table 60: Helena. Products Portfolio

Table 61: Global Market Value (USD Million) (2025-2032) By Type

Table 62: Global Market Share (%) By Type (2032)

Table 63: Global Market Value (USD Million) (2025-2032) By Application

Table 64: Global Market Share (%) By Application (2032)

Table 65: Global Market Volume (K) (2025-2032) By Type

Table 66: Global Market Share (%) By Type (2032)

Table 67: Global Market Volume (K) (2025-2032) By Application

Table 68: Global Market Share (%) By Application (2032)

Table 69: Global Helicobacter Pylori Tester Without Endoscopy Market Value (USD Million) By Region

Table 70: Global Helicobacter Pylori Tester Without Endoscopy Market Share (%) By Region (2025-2032)

Table 71: North America Market Value (USD Million) (2025-2032) By Country

Table 72: North America Market Value (USD Million) (2025-2032) By Type

Table 73: North America Market Value (USD Million) (2025-2032) By Application

Table 74: Europe Market Value (USD Million) (2025-2032) By Country

Table 75: Europe Market Value (USD Million) (2025-2032) By Type

Table 76: Europe Market Value (USD Million) (2025-2032) By Application

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 80: South America Market Value (USD Million) (2025-2032) By Country

Table 81: South America Market Value (USD Million) (2025-2032) By Type

Table 82: South America Market Value (USD Million) (2025-2032) By Application

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 86: Global Helicobacter Pylori Tester Without Endoscopy Market Volume (K) By Region

Table 87: Global Helicobacter Pylori Tester Without Endoscopy Market Share (%) By Region (2025-2032)

Table 88: North America Market Volume (K) (2025-2032) By Country

Table 89: North America Market Volume (K) (2025-2032) By Type

Table 90: North America Market Volume (K) (2025-2032) By Application

Table 91: Europe Market Volume (K) (2025-2032) By Country

Table 92: Europe Market Volume (K) (2025-2032) By Type

Table 93: Europe Market Volume (K) (2025-2032) By Application

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 95: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 97: South America Market Volume (K) (2025-2032) By Country

Table 98: South America Market Volume (K) (2025-2032) By Type

Table 99: South America Market Volume (K) (2025-2032) By Application

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 101: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 103: Research Programs/Design For This Report

Table 104: Key Data Information From Secondary Sources

Table 105: Key Data Information From Primary Sources

FAQs

1. What is the current Helicobacter Pylori Tester Without Endoscopy market size?

The Helicobacter Pylori Tester Without Endoscopy market size reached USD 640 million in 2023, propelled by rising preference for non-invasive testing across outpatient and primary-care settings globally.

2. What is the forecasted growth rate for the next five years?

Analysts project an 8.1% CAGR through 2028, driven by expanding stool antigen and urea breath test adoption, pushing the market beyond USD 940 million by the end of the forecast window.

3. What are the key drivers behind market expansion?

High prevalence of dyspepsia, growing aversion to invasive endoscopy, rapid serology and breath-test innovations, supportive reimbursement, and heightened antibiotic-resistance surveillance collectively accelerate demand for Helicobacter Pylori Tester Without Endoscopy solutions.

4. Which challenges could restrain growth?

Accuracy variability in low-prevalence cohorts, limited public awareness, price pressure in cost-sensitive regions, and fragmented regulatory pathways complicate commercialization and uptake of non-invasive H. pylori testing.

5. Which regions lead adoption?

North America and Europe dominate owing to robust primary-care infrastructure, favorable reimbursement, and strong antibiotic-stewardship programs, while East Asia shows the fastest growth on healthcare modernization and rising gastric cancer screening initiatives.

6. Who are the top companies shaping competitive dynamics?

Market leaders include DiaSorin, Meridian Bioscience, Sekisui Diagnostics, QuidelOrtho, and Thermo Fisher, each leveraging CLIA-waived platforms, monoclonal antigen improvements, and global distribution contracts to secure share.

7. What future opportunities lie ahead?

Point-of-care breath strips, AI-interpreted lateral-flow readers, multiplex GI panels, and strategic tie-ups with telehealth platforms represent high-value opportunities within the Helicobacter Pylori Tester Without Endoscopy future outlook.

8. How is technology impacting test performance?

Next-generation monoclonal antibodies, stable isotope breath analysis, smartphone-based result capture, and cloud-based algorithms enhance sensitivity above 95%, shorten turnaround time, and widen decentralized deployment.

9. What is the current regulatory landscape?

FDA 510(k) clearances emphasize clinical concordance with endoscopy, while Europe’s IVDR demands post-market vigilance and evidence of antibiotic resistance correlation; many Asian regulators now align with WHO pre-qualification standards.

10. Will reimbursement policies affect market penetration?

Yes, expanding CPT codes for non-invasive H. pylori assays in the U.S. and incremental NICE guidelines in the U.K. reduce patient out-of-pocket costs, accelerating adoption and positively shaping the future outlook.

Contact for Full Report

Loading report content...

Helicobacter Pylori Tester Without Endoscopy Market: Opportunity by 2034 | In-Depth Report

Market Snapshot

Helicobacter Pylori Tester Without Endoscopy Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Helicobacter Pylori Tester Without Endoscopy Segmentation

Helicobacter Pylori Tester Without Endoscopy Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Helicobacter Pylori Tester Without Endoscopy market size?

2. What is the forecasted growth rate for the next five years?

3. What are the key drivers behind market expansion?

4. Which challenges could restrain growth?

5. Which regions lead adoption?

6. Who are the top companies shaping competitive dynamics?

7. What future opportunities lie ahead?

8. How is technology impacting test performance?

9. What is the current regulatory landscape?

10. Will reimbursement policies affect market penetration?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Helicobacter Pylori Tester Without Endoscopy Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Helicobacter Pylori Tester Without Endoscopy Segmentation

Helicobacter Pylori Tester Without Endoscopy Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Helicobacter Pylori Tester Without Endoscopy market size?

2. What is the forecasted growth rate for the next five years?

3. What are the key drivers behind market expansion?

4. Which challenges could restrain growth?

5. Which regions lead adoption?

6. Who are the top companies shaping competitive dynamics?

7. What future opportunities lie ahead?

8. How is technology impacting test performance?

9. What is the current regulatory landscape?

10. Will reimbursement policies affect market penetration?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation